Pharmacokinetics of chlorofluorocarbon and hydrofluoroalkane metered-dose inhaler formulations of beclomethasone dipropionate

AIMS: To compare the pharmacokinetic profile of Beclazone (beclomethasone dipropionate) in its chlorofluorocarbon (CFC)-based and CFC-free formulations. METHODS: Ten healthy adults received a single 1,000 microg nominal dose (ex-valve) of beclomethasone dipropionate from a CFC inhaler (BEC-CFC) or from a CFC-free inhaler containing hydrofluoroalkane (HFA)-134a (BEC-HFA) in an open-label, randomized, two-way, crossover study. Blood samples were collected predose and over 12 h after inhalation. Comparisons were made of maximum plasma concentration of beclomethasone 17-monopropionate (17-BMP) (Cmax), and area under the plasma concentration vs time curve (AUC). RESULTS: The tmax was significantly (P<0.05) earlier with BEC-HFA and plasma levels were significantly higher following administration of BEC-HFA than BEC-CFC. Geometric mean values for AUC were 1.5 fold greater (90% CI 1.3-1.9) and for Cmax were 1.9 fold greater (90% CI 1.6-2.6) following BEC-HFA than BEC-CFC. CONCLUSIONS: Our data in healthy volunteers would not be consistent with the manufacturers' recommendation for a microgram equivalent (1:1) nominal dose switch between these HFA and CFC formulations. Further well designed trials are required in asthmatic patients to properly define their respective dose-response relationships for antiasthmatic and systemic adverse effects.     

Inhaled steroids and the risk of adrenal suppression in children

Corticosteroids are the mainstay of treatment of all asthma severity levels in adults and children. With their widespread use comes a responsibility to monitor, understand, and balance their efficacy and safety. Systemic adverse effects such as adrenal suppression have been clearly associated with the use of oral corticosteroids and to a lesser degree with the use of inhaled corticosteroids (ICS). In clinical trials, adrenal suppression is more evident when ICS are used in long-term therapy and at higher doses. However, monitoring adrenal suppression during short-term therapy and at lower doses is still of value in order to ascertain the lower limit of an inhaled corticosteroid’s safety profile. Significant adrenal suppression at conventional ICS doses appears to be rare in clinical practice. When evaluating the effect of ICS on the hypothalamo-pituitary-adrenal-axis (HPA-axis), one must consider sources of variability both within and among trials including test sensitivity, systemic bioavailability, degree of airway obstruction, and delivery devices. All of these factors have the potential to effect the level of adrenal suppression detected and must be considered when interpreting HPA-axis test results in research or practice. This review will discuss adrenal suppression found with common ICS.     

Systemic bioavailability of fluticasone propionate administered as nasal drops and aqueous nasal spray formulations

AIMS: To measure and compare the systemic bioavailability of fluticasone propionate aqueous nasal spray and a new nasal drop formulation, using a sensitive analytical method and high dose regimen. METHODS: Volunteers received four 800 microg doses of fluticasone propionate as a nasal spray or drops over 2 days, separated by an 8 h dose interval. On day 2, blood samples were collected for assay of fluticasone propionate plasma concentrations. RESULTS: The mean systemic exposure, for both formulations was 8.5 pg x ml(-1) x h (drops) and 67.5 pg x ml(-1) x h (spray). Mean absolute bioavailabilities were estimated to be 0.06% (drops) and 0.51% (spray), by reference to historical intravenous data. CONCLUSIONS: Both formulations exhibited low systemic bioavailability, even at 12 times the normal daily dose. The bioavailability from the nasal drops was approximately eight times lower than from the nasal spray.     

Respirable dose delivery of fluticasone propionate from a small valved holding chamber, a compact breath actuated integrated vortex device and a metered dose inhaler

AIMS

To compare the respirable dose delivery of the hydrofluroalkane fluticasone propionate (HFA-FP) via an optimally prepared Aerochamber Plus spacer (AP), via a Synchro-Breathe (SB) device, and pMDI Evohaler (EH).

METHODS

Seventeen mild to moderate asthmatics completed the study using a randomized, double-blind, double-dummy, three way crossover design. Single doses of placebo or HFA-FP 2.0 mg were administered via the EH, AP, and SB devices. The overnight urinary cortisol : creatinine ratio (OUCC) was measured at baseline and after each dose.

RESULTS

Significant suppression of OUCC occurred from baseline with AP and SB but not EH devices (geometric mean fold suppression, 95% CI): AP: 3.18 (2.29, 4.36), P < 0.001; SB: 1.79 (1.31, 2.40), P = 0.001; EH: 1.12 (0.69, 1.44), p = 0.37 (equating to 68%, 45% and 9% falls, respectively). Significant differences in OUCC between devices were as follows: (geometric mean fold difference, 95% CI): AP vs. EH. 2.83 (2.09, 3.82), P < 0.001; AP vs. SB: 1.78 fold (1.21, 2.60), P = 0.003; SB vs. EH: 1.59 (1.09, 2.31), P = 0.013 (equating to 65%, 44% and 37% differences, respectively).

CONCLUSIONS

The use of an optimally prepared AP spacer and breath actuated SB device, when compared with pMDI, significantly increased the respirable dose of HFA-FP.

WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT

• Respirable dose delivery of inhaled steroids may be improved by the use of conventional valved holding chambers (such as the Aerochamber Plus spacer), but these are bulky and cumbersome to use.
• A novel compact breath actuated device with integrated vortex chamber (Synchro-Breathe) has been developed to overcome these problems,
• The lung bioavailability of inhaled fluticasone propionate is dependant on respirable dose delivery, and hence the performance of inhaler devices can be quantified by measuring the degree of adrenal suppression as a surrogate for relative lung dose.

WHAT THIS STUDY ADDS

• This study compares the respirable dose delivery (as relative adrenal suppression) of inhaled fluticasone delivered via Synchro-Breathe, conventional pMDI (Evohaler), and an optimally prepared Aerochamber Plus spacer in patients with asthma.
• The Aerochamber Plus and the Synchro-Breathe devices produced significantly higher respirable dose delivery of inhaled fluticasone than the pMDI, in terms of the relative degree of adrenal suppression.

     

Adrenal axis suppression unrelated to the dynamics of dosing with beclomethasone monopropionate

AIMS: Inhaled corticosteroids (ICS) are the cornerstone of asthma treatment. At high doses they can give rise to systemic side-effects such as hypothalamic-pituitary-adrenal (HPA) axis suppression. This effect may depend on the delivery system, which in turn alters drug deposition and adsorption. We hypothesized that adrenal suppression depends on the rate of steroid absorption rather than the total steroid dose received. METHODS: Eight healthy adult males were recruited for a randomized double-blind placebo controlled trial. Adrenocortical suppression ability was demonstrated by a 30% suppression of early morning cortisol following 1 mg dexamethasone. Subjects then attended in the evening on two occasions receiving 500 microg of intravenous beclomethasone monopropionate (17-BMP) for either 15 min or 2 h. Overnight urinary cortisol : creatinine (C : C) ratio was measured before and after the infusion and an 08.00 h serum cortisol was measured following the infusion. RESULTS: Mean C : C pre and post 15 min infusion was 5.97 and 3.22 (P = 0.005). Mean C : C pre and post 2 h infusion was 6.31 and 4.15 (P = 0.004). Delta C : C and mean 08.00 h cortisol for 15 min and 2 h infusion was 2.74 and 2.16 and 425 nmol l(-1) and 400 nmol l(-1), respectively (P = NS). CONCLUSIONS: The rate of infusion of 17-BMP seemed to have little effect on the degree of adrenal suppression. Individual C : C ratios were reproducible. Differences in absorption of ICS are unlikely to explain observed differences in HPA axis suppression.     

Pharmacokinetics and systemic effects of inhaled fluticasone propionate in healthy subjects

Aims The present study was undertaken to see whether the difference in plasma cortisol suppression between single and repeated dosing of fluticasone propionate (FP) can be explained by systemic accumulation.
Methods Twelve healthy subjects (six women) were given, in a crossover fashion, a single dose inhalation (1000  &;mgr;g) of FP via Diskhaler and repeated inhalations (1000  &;mgr;g twice daily) every 12  h during 7 days. There was a washout period of 2 weeks between the treatments. An intravenous dose of 20  μg FP was given as a reference. Plasma concentrations of FP for each treatment were determined by liquid chromatography plus tandem mass spectrometry. Plasma cortisol after the inhaled doses was determined using an immunoassay and was compared with baseline values.
Results The average plasma concentration of FP was about 1.7 times higher after multiple inhalations than after a single dose. Systemic availability, mainly attributable to pulmonary deposition, was 15.6 [13.6–18.0]% of the nominal dose. Daytime plasma cortisol suppression vs baseline was 47 [20–65]% and 95 [93–97]% for the single and repeated doses, respectively.
Conclusions To conclude, a slow elimination of FP leads to accumulation during repeated dosing. This accumulation may explain the marked decrease in plasma cortisol seen during treatment with fluticasone propionate within the clinical dose range.     

A placebo-controlled,blind comparison of nedocromil sodium and beclomethasone dipropionate in bronchial asthma

Summary

A multi-centre, randomized, blind comparative group study was carried out in 202 adult patients, who had suffered from asthma for at least 2 years, to assess the effectiveness and tolerability of maintenance treatment with either 4?mg nedocromil sodium 4-times daily, 0.1?mg beclomethasone dipropionate 4-times daily or 2 puffs of placebo 4-times daily, given by inhalation. Lung function (FEY₁ and sRaw) measurements were made at the beginning and end of a 2-week baseline period and then after 3 and 6 weeks of treatment: assessments were also made of asthma severity. Patients recorded daily on diary cards details of morning and evening PEFR, usage of inhaled bronchodilators, severity of dyspnoea, cough and morning tightness. The results showed that, compared with placebo, both nedocromil sodium and beclomethasone dipropionate-treated patients showed an improvement in FEY₁and a reduction in sRaw values: PEFR increased slightly in all three groups. There was an improvement in asthma severity, diminished rate of dyspnoea and cough, and reduced usage of inhaled bronchodilators in patients receiving active treatment but not in those on placebo. Overall assessment of treatment efficacy by both investigators and patients showed that opinions were significantly in favour of active treatment over placebo. Treatment was well tolerated and no serious side-effects were reported. It was concluded that at the dosages used nedocromil sodium was comparable with and equivalent to inhaled beclomethasone dipropionate in nearly all of the parameters assessed, and both drugs were superior to placebo in the maintenance treatment of asthma in adult patients.     

Comparison of flunisolide and beclomethasone dipropionate in seasonal allergic rhinitis

Summary

Sixty-nine patients were entered into a randomized, single-blind, parallel group study. Patients had a history of moderate to severe seasonal allergic rhinitis and all patients commenced treatment before the start of the pollen season. Treatment was with either flunisolide or beclomethasone dipropionate, both being administered as 2 sprays to each nostril twice daily for 7 weeks. Assessments of signs and symptoms of hay fever were made at admission and after 3 and 7-weeks' treatment. Patients were asked to keep a daily record of the severity of their symptoms. The overall effect of treatment was evaluated by both the patient and physician. Side-effects were elicited by indirect questioning. Sixty patients completed the study. Four patients from the flunisolide group and 2 from the beclomethasone group were lost to follow-up. Two further patients withdrew from the flunisolide group and 1 from the beclomethasone group. Analysis of results did not reveal any statistically significant differences between the treatments. Minor side-effects were reported by 1 patient from each treatment group. Both treatments proved to be effective in the treatment of hay fever and were equally well tolerated.     

高效液相色谱内标法测定无极膏中丙酸倍氯米松的含量

目的建立测定无极膏中丙酸倍氯米松含量的方法。方法采用C18柱（4．6mm×250mm,5um）,以甲醇·水（75：25）为流动相,流速为1．0ml·min^-1,检测波长240nm,用内标法测定,内标物为醋酸氯地孕酮。结果丙酸倍氯米松在2．09—41．76mg·L^-1范内呈良好线性关系（r=1）,平均回收率为100．96％,RSD为1．6％。结论该方法准确,可靠,可用于无极膏的质量控制。     

Pharmacokinetics and dose proportionality of beclomethasone from three strengths of a CFC-free beclomethasone dipropionate metered-dose inhaler

As part of a development program to offer alternatives to chlorofluorocarbon (CFC) containing metered-dose inhalers, beclomethasone dipropionate has been formulated in a CFC-free system at three strengths: 50, 100, and 200 μg/actuation ex valve. To measure serum levels and dose proportionality of the beclomethasone derived from beclomethasone dipropionate, 13 mild to moderate asthmatic patients received a single dose of eight inhalations from each strength according to a double-blind crossover design. Seven patients were studied over 4 h and six patients over 12 h. For the total doses of 400, 800, and 1600 μg studied over 12 h, C_max and AUC increased in a ratio of 1:1·8:3·1. A good correlation was seen between the fine-particle mass delivered and the in vivo performance of the three strengths. From a clinical point of view, the predictable increases in serum levels with an increase in dose will permit the clinician to effectively titrate a patient with this product. © 1997 John Wiley & Sons, Ltd.     

丙酸氟替卡松局部治疗鼻息肉作用机制的探讨

目的 观察丙酸氟替卡松对体外培养的鼻息肉成纤维细胞生长及凋亡的影响,以探讨其局部治疗鼻息肉的可能机制.方法 取11例鼻息肉患者的鼻息肉组织进行传代培养后获得鼻息肉成纤维细胞,观察在不同体积分数(2%、4%、8%)丙酸氟替卡松作用铝、72、96和120 h对成纤维细胞活力的影响;采用流式细胞仪和Hoechest染色观察丙酸氟替卡松(体积分数为4%)作用48、72、96和120 h时对成纤维细胞凋亡的影响,并与空白对照组进行对比.结果 与空白对照组相比,当丙酸氟替卡松的体积分数>4%时能显著抑制成纤维细胞的生长(P<0.05).流式细胞仪和Hoechest染色结果表明,体积分数为4%的丙酸氟替卡松能导致成纤维细胞凋亡.与空白对照组对比差异有统计学意义(P<0.05).结论 丙酸氟替卡松体外能抑制鼻息肉成纤维细胞的生长并诱导其凋亡.     

沙美特罗替卡松吸入治疗儿童哮喘的疗效观察及护理

目的:观察沙美特罗替卡松吸入治疗儿童哮喘的疗效和护理方法。方法:按病情轻、中、重度持续不同,分别给予不同剂量沙美特罗替卡松吸入,同时按需使用短效β2受体激动剂吸入,对<7岁的患儿可加用储雾罐。并由专科护士讲解使用方法。结果:治疗2周后,日间、夜间症状、肺部哮鸣音评分显著下降,治疗至6个月时无症状的病例已达99.15%,治疗2周后用万托林的量明显减少。6月时有记录的357例随访中显效355例(99.4%),有效1例(0.3%),无效1例(0.3%),总有效率99.7%。结论:沙美特罗替卡松治疗哮喘,只要用量恰当,吸入的方法正确,可以减少哮喘发作的次数和减轻哮喘发作的程度。     

丙酸氟替卡松治疗过敏性鼻炎疗效及对患者免疫力的影响

目的 探讨丙酸氟替卡松治疗过敏性鼻炎疗效及对患者免疫力的影响.方法 选取该院2010年1月-2012年12月收治的80例过敏性鼻炎患者进行研究分析.80例患者按照数字随机法分为观察组和对照组,每组40例.观察组采用丙酸氟替卡松治疗,对照组采用酮替芬进行治疗,观察两组患者治疗的效果及治疗前后血清中血清免疫球蛋白（Ig）定量和IL-4及IL-12的含量变化.结果 经研究发现,观察组有效率95.0%,与对照组80.0%相比,差异具有统计学意义,P〈0.05.且治疗后,IL-4、IL-12 的含量明显高于治疗前和对照组,差异均具有统计学意义,P〈0.05.结论 丙酸氟替卡松在治疗过敏性鼻炎有较好的疗效,且患者免疫力大大提高,值得临床推荐.     

Adrenal suppression with high doses of inhaled fluticasone propionate and triamcinolone acetonide in healthy volunteers

Study objective: This study was conducted to compare the adrenal suppression of inhaled fluticasone propionate and triamcinolone acetonide in healthy volunteers, both given via their respective pressurised metered dose inhaler (pMDI) devices at high doses within the manufacturers recommended dose range. Design: We used a single (investigator) blind, randomised, crossover design comparing a total daily dose of 1.625 mg fluticasone propionate delivered via a pMDI, 1.60 mg daily of triamcinolone acetonide delivered via a pMDI with integrated spacer, or placebo pMDI; each drug was given in two divided doses at 0800 hours and 2200 hours over a 24-h period. Each drug treatment was separated by a 1-week washout. Patients: Twelve normal subjects mean age 27.5 years were studied. Measurements: Blood samples were taken for 0800 hours plasma cortisol, i.e. 10 h following the second dose. Ten hour urine collections (2200 hours until 0800 hours) were taken for urinary cortisol and creatinine excretion. Results: For the 0800 hours plasma cortisol (geometric mean, nmol · l⁻¹) compared with placebo (353) fluticasone propionate (138) produced significant (P<0.05) suppression (2.57-fold difference), whereas triamcinolone acetonide (263) did not (1.34-fold difference). Fluticasone propionate produced a 1.91-fold greater adrenal suppression than triamcinolone acetonide (95% CI 1.10 to 3.33). Individual subjects with abnormally low 0800 hours cortisol values <150 nmol · l⁻¹ (<5.4 μg/dl) were n=4 for fluticasone propionate and n=0 for triamcinolone acetonide. Overnight urinary cortisol/creatinine ratio (geometric mean, nmol/mmol) did not show any difference between fluticasone propionate (1.48) and triamcinolone acetonide (1.60), with both producing significant suppression versus placebo (4.01): triamcinolone acetonide 2.50-fold difference (95% CI 1.45–4.24); fluticasone propionate 2.71-fold difference (95% CI 1.57–4.69). Conclusion: Fluticasone propionate 1.625 mg/day (pMDI) produced an approximately two-fold greater adrenal suppression of 0800 hours plasma cortisol than triamcinolone acetonide 1.60 mg per day (Oral Inhaler) when given twice daily, and one third of subjects with fluticasone had abnormally low 0800 hours cortisol values <150 nmol · l⁻¹ (<5.4 μg · dl⁻¹). There were no differences between the drugs for urinary cortisol excretion. Further dose-ranging studies are required at steady-state in asthmatic subjects in order to see whether differences occur at lower doses on the steep part of the dose–response curve for both plasma and urinary cortisol suppression. Received: 28 January 1997 / Accepted in revised form: 11 April 1997     

丙酸氟替卡松鼻喷雾剂对儿童哮喘控制及过敏性鼻炎症状改善的作用

目的 比探讨丙酸氟替卡松鼻喷雾剂在改善儿童过敏性鼻炎症状以及控制哮喘反复发作方面的作用.方法 将100例过敏性鼻炎合并哮喘综合征患儿按照随机数字表法分为对照组和观察组.对照组应用氯雷他定及经口腔吸人糖皮质激素,观察组在此基础上使用丙酸氟替卡松鼻喷雾剂治疗,观察两组疗效.结果 观察组总有效率（94％）明显优于对照组（76％）（x2=6.35,P＜0.05）.10 ～ 12周以后,观察组与对照组鼻炎症状评分及哮喘症状评分差异均有统计学意义（t=2.47、2.64、3.41;2.30、3.17、2.47,均P＜0.05）.不良反应方面两组鼻腔干燥、鼻出血发生率差异均有统计学意义（x2 =7.11、7.53,均P＜0.05）.结论 丙酸氟替卡松鼻喷雾剂在改善儿童过敏性鼻炎和哮喘症状复发方面有很好疗效,值得临床大力推广.     

Short-term dose-response relationships for the relative systemic effects of oral prednisolone and inhaled fluticasone in asthmatic adults

AIMS: To determine the systemic dose-response relationships with oral prednisolone and inhaled fluticasone propionate administered in a putative 11:1 mg equivalent basis, in terms of effects on adrenal, bone and haematological markers. METHODS: Twelve asthmatic patients mean (s.e.) age, 28.8 [3.3] years, FEV1 94.7 [3.6]% predicted, FEF(25-75) 65.5 [6.1]% predicted were studied in a double-blind, double dummy randomised crossover design comparing placebo, inhaled fluticasone propionate via volumatic spacer given twice a day (ex actuator dose 0.44 mg day-1, 0.88 mg day-1, 1.76 mg day-1 ) and oral prednisolone given once daily (5 mg day-1, 10 mg day-1, 20 mg day-1 ). All treatments were for 4 days at each dose level with a 7-day washout at crossover. Measurements were made at 08.00 h after the last dose of each dose level for plasma cortisol, serum osteocalcin and blood eosinophil count. RESULTS: There were significant dose-related effects for suppression of all three endpoints with both prednisolone and fluticasone propionate. Parallel slope analysis revealed a calculated dose ratio for relative potency of 8. 5:1 mg (95% CI 5.7-11.2) comparing Pred with FP for morning cortisol. The magnitude of suppression with FP was less for osteocalcin and eosinophils than for cortisol. CONCLUSIONS: Systemic tissues exhibit different dose-response relationships for the effects of inhaled and oral corticosteroids with suppression of cortisol being greater than osteocalcin or eosinophils. For cortisol suppression we observed an 8.5:1 mg relative potency ratio comparing prednisolone with fluticasone propionate. Patients taking high dose inhaled fluticasone propionate should therefore be screened for evidence of impaired adrenal reserve.     

Pharmacokinetic/pharmacodynamic evaluation of urinary cortisol suppression after inhalation of fluticasone propionate and mometasone furoate

AIM: Fluticasone propionate (FP) and mometasone furoate (MF) are inhaled corticosteroids that possess a high ratio of topical to systemic activity. The systemic bioavailability of MF has been claimed to be minimal (1%). FP has been shown to exhibit the same degree of systemic effects, but its systemic availability is between 13 and 17%. We hypothesize that FP and MF have comparable systemic availabilities that can explain their potential to cause systemic effects. METHODS: Steady-state FP and MF trough plasma samples were determined from a clinical study by Fardon et al. in patients with persistent asthma (forced expiratory volume in 1 s = 91%). The percent plasma protein binding of FP and MF was measured using ultracentrifugation. Free FP plasma concentrations were normalized for their differences in receptor binding affinity compared with MF and linked to overnight urinary cortisol/creatinine with an inhibitory E(max). RESULTS: A plot of steady-state FP and MF total trough plasma concentrations vs. dose showed that both drugs exhibit dose linearity. MF has comparable bioavailability to FP based on the steady-state concentrations observed for the different doses. The free plasma concentration producing 50% of urinary cortisol suppression (IC(50)) for MF was not statistically different from the free, normalized IC(50) for FP. CONCLUSION: FP and MF have similar pulmonary deposition and the same potential to cause systemic side-effects due to their similar IC(50) values. The observed urinary cortisol suppression of FP and MF is in agreement with their systemic availability, their differences in plasma protein binding and receptor binding affinity.     

沙美特罗替卡松粉吸入剂配合氨茶碱治疗哮喘的效果探讨

目的 探讨采用沙美特罗替卡松粉吸入剂配合氨茶碱治疗哮喘的临床效果.方法 随机选取本院2013年2月至2015年4月期间收治的哮喘患者94例,按照患者意愿将其分为观察组和对照组,其中对照组患者仅采用沙美特罗替卡松粉吸入剂进行治疗,观察组患者则在对照组的治疗基础上结合氨茶碱进行治疗,对两组患者临床症状的改善情况进行观察对比.结果 观察组患者的临床治疗总有效率、临床症状改善情况均明显高于对照组,差异具有统计学意义(P＜0.05).结论 氨茶碱联合沙美特罗替卡松粉吸入剂是一种有效的哮喘治疗方案,能够显著改善患者的临床症状,建议在临床上进一步推广.     

Detection of fluticasone propionate in horse plasma and urine following inhaled administration

Fluticasone propionate (FP) is an anti‐inflammatory agent with topical and inhaled applications commonly used in the treatment of asthma in steroid‐dependent individuals. The drug is used in racehorses to treat Inflammatory Airway Disease; this work was performed in order to advise on its use and detect potential misuse close to racing. Methods were developed for the extraction and analysis of FP from horse plasma and a carboxylic acid metabolite (FP‐17βCOOH) from horse urine. The methods utilize ultra high performance liquid chromatography coupled to tandem mass spectrometry (UPLC‐MS/MS) in order to detect the extremely low concentrations of analyte present in both matrices. The developed methods were used to analyse plasma and urine samples collected following inhaled administration of FP to six thoroughbred horses. FP was detected in plasma for a minimum of 72 h post‐administration and FP‐17βCOOH was detected in urine for approximately 18 h post‐administration. The results show that it is possible to detect FP in the horse following inhaled administration. Copyright © 2012 John Wiley & Sons, Ltd.     

沙美特罗替卡松治疗慢性阻塞性肺疾病急性加重期临床研究

目的探讨沙美特罗替卡松治疗慢性阻塞性肺疾病急性加重期疗效。方法将笔者所在医院2012年1月～2012年4月收治的COPD急性加重期患者分为实验组和对照组,对照组患者给予一般治疗,实验组患者在对照组基础上加用沙美特罗替卡松治疗,观察两组患者临床症状改善情况以及SGRQ评分。结果实验组治疗后其喘息、咳嗽、哮鸣音等临床症状改善情况均明显优于对照组(P<0.05),治疗后SGRQ评分明显优于对照组,差异有统计学意义(P<0.05)。结论沙美特罗替卡松对慢性阻塞性肺疾病急性加重期安全有效,可显著改善患者肺功能,值得在临床工作中推广应用。